ClinicalTrials.gg
Active, not recruitingNCT05893979BIRCHUpdated May 5, 2026

Myopia Control Spectacle Lens Cessation Study

An interventional study of Spectacle Lenses in Myopia, Myopia Progression and Juvenile Myopia, sponsored by SightGlass Vision, Inc.. Active, not recruiting at 8 sites in United States. Open to participants aged 9 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
9 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..

Planned enrollment
7th of 14
90 · median 71
Started
2023
with 3 others
No phase
14 of 14
3 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
10th of 14
by date

Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 7th largest by planned enrollment, is one of 4 that started in 2023, is one of 14 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 10th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 9 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myopia by SightGlass Vision, Inc., or all of them as a file.
02

Study summary

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses.

To quantify axial length progression following cessation of use of specific spectacle lenses.

03

Conditions studied

  • Myopia
  • Myopia Progression
  • Juvenile Myopia

Browse trials for

04

Who can participate

Ages eligible
9 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously a successfully completed participant in the CYPRESS Extension study;
  • Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);
  • Willingness to participate in the trial for up to 12 months without contact lens wear;
  • The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of and receive a fully executed copy of the form.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to proparacaine, tetracaine, or tropicamide.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Test Lens Group

    Device: Spectacle Lenses

  • Active comparator
    Control Lens Group

    Device: Spectacle Lenses

Interventions

  • DeviceSpectacle Lenses

    Standard Spectacle Lenses

06

What researchers measure

Primary outcomes

  1. Cycloplegic Spherical Equivalent Refraction (cSER)

    Change in cSER

    Time frame: 12 months

Secondary outcomes

  1. Cycloplegic Spherical Equivalent Refraction (cSER)

    Change in cSER

    Time frame: 6 months

  2. Axial Length (AL)

    Change in AL

    Time frame: 12 months

07

Study locations

8 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 42 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Jun 8, 2023
StartActual
Jun 23, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 31, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05893979
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
Jun 23, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion